Reportedly, loss and down-regulation of Beclin 1 expression was immunohistochemically observed in esophageal adenocarcinoma (64), colorectal cancer (65), breast cancer (66), but versa in pancreatic cancer (67). This evidence concerns the gene BECN1 and esophageal adenocarcinoma.